Market revenue in 2023 | USD 666.8 million |
Market revenue in 2030 | USD 1,490.2 million |
Growth rate | 12.2% (CAGR from 2023 to 2030) |
Largest segment | Therapeutics |
Fastest growing segment | Diagnostics |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Diagnostics, Therapeutics |
Key market players worldwide | Roche, Siemens Healthineers AG ADR, Janssen Pharmaceuticals, Illumina Inc, Quest Diagnostics Inc, 23andMe Holding Co Class A, NeoDiagnostix, International Business Machines Corp, Myriad Genetics Inc, Medtronic PLC, GE HealthCare Technologies Inc Common Stock, Abbott Laboratories, Dakota Software, Biogen Inc, Qiagen NV, ImmunityBio Inc Ordinary Shares |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to precision medicine market will help companies and investors design strategic landscapes.
Therapeutics was the largest segment with a revenue share of 81.16% in 2023. Horizon Databook has segmented the Denmark precision medicine market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.
Denmark is boosting its position as a leader in precision medicine research. In 2022, the University of Copenhagen welcomed its first cohort of graduate students in precision medicine, targeting professionals aiming to enhance their skills in data science, clinical decision-making, and the ethics of PM.
Furthermore, Denmark launched its first quantum computer program at the Niels Bohr Institute, intending to develop the world’s first fully functional, generally applicable quantum computer by 2034. The Novo Nordisk Foundation has donated over USD 200 million to this initiative, anticipating that the advanced computational power will aid in analyzing vast amounts of genetic data to create new PM treatments.
Novo Nordisk is particularly optimistic about applying PM to treat type 1 diabetes. In November 2022, the Novo Nordisk Foundation hosted 'The Future of Precision Medicine Symposium' for the second time, featuring discussions on topics like trans-ethnic perspectives and the role of AI in PM. This event highlights the commitment of both private and public sectors in Denmark to advancing PM research.
Horizon Databook provides a detailed overview of country-level data and insights on the Denmark precision medicine market , including forecasts for subscribers. This country databook contains high-level insights into Denmark precision medicine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account